Ziv-aflibercept
Modify Date: 2025-09-18 17:26:29
Ziv-aflibercept structure
|
Common Name | Ziv-aflibercept | ||
|---|---|---|---|---|
| CAS Number | 1609655-49-3 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Ziv-afliberceptZiv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases[1][2]. |
| Name | Ziv-aflibercept |
|---|
| Description | Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Ziv-aflibercept (0.25、0.5、1.0 和 5 mg/mL；24 h) 以剂量依赖性方式降低 ARPE-19 细胞的线粒体膜电位[1]。 Cell Viability Assay[1] Cell Line: ARPE-19 cells. Concentration: 0.25, 0.5, 1.0 and 5 mg/mL. Incubation Time: 24 h. Result: Insignificantly affected cell viability (below 1 mg/mL). |
| In Vivo | Ziv-aflibercept (25 mg/mL；眼内注射；单剂量) 在兔子右眼中没有显著引起白内障、视网膜脱离等相关并发症[2]。 |
| References |
| No Any Chemical & Physical Properties |